Streetbeat News

Earnings

FRD

Friedman Industries anticipates a strong Q4 in fiscal year 2024, driven by solid margins from a substantial increase in HRC price and a slight increase in sales volume compared to Q3.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 10:17 pm

FRD

Friedman Industries reported a decrease in Q3 EPS to $0.16 from $0.19 YoY, while sales increased to $115.97M from $111.86M YoY.

Portfolio Pulse from Happy Mohamed

February 14, 2024 | 10:16 pm

CTXR

Citius Pharma (NASDAQ:CTXR) reported a Q1 EPS loss of $(0.06), a 200% increase in losses compared to $(0.02) per share from the same period last year.

Portfolio Pulse from Happy Mohamed

February 14, 2024 | 10:14 pm

MVBF

MVB Financial (NASDAQ:MVBF) reported Q4 earnings of $0.61 per share, surpassing the $0.33 estimate, marking an 84.85% beat and a 22% increase from last year. However, their Q4 sales of $35.55M fell short of the $37.96M estimate, a 6.36% miss and a 10.63% decrease from the previous year.

Portfolio Pulse from Happy Mohamed

February 14, 2024 | 10:13 pm

KAI

Kadant Inc. has projected its Q1 revenue to be between $238M-$246M, surpassing the estimated $232.85M. However, its adjusted EPS is expected to be $1.90-$2.00, below the estimated $2.29.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 10:12 pm

RIG

Transocean Ltd. (NYSE:RIG) released its quarterly Fleet Status Report, revealing an aggregate incremental backlog of approximately $326 million from new contracts in the Romanian Black Sea, Angola, and the U.S. Gulf of Mexico. The company's total backlog as of February 14, 2024, stands at about $9 billion.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 10:11 pm

KAI

Kadant Inc. has projected its 2024 revenue to be between $1.04 billion and $1.065 billion, surpassing the estimated $968.02 million. Additionally, the company expects its adjusted EPS to range from $9.75 to $10.05, which is around the estimated $9.86.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 10:10 pm

DYN

Dyne Therapeutics, Inc. (NASDAQ:DYN) announced its participation in the 2024 Muscular Dystrophy Association Clinical & Scientific Conference with two presentations on initial clinical data from its ACHIEVE and DELIVER trials in DM1 and DMD patients, respectively. The data, first reported in January 2024, demonstrated proof-of-concept for its DM1 and DMD programs, validating the FORCE platform's targeted delivery to muscle. Additional data from these trials is expected in the second half of 2024. The ACHIEVE trial evaluates DYNE-101 in DM1 patients, while the DELIVER trial assesses DYNE-251 in DMD patients amenable to exon 51 skipping. Both trials have shown promising initial results and safety data.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 10:09 pm

FORD

Forward Industries reported Q1 earnings with a per-share loss of $(0.04), unchanged from last year, and a 26.67% decrease in sales to $7.15M from $9.75M YoY.

Portfolio Pulse from Happy Mohamed

February 14, 2024 | 10:08 pm